We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Topline results from a phase 2b/3 clinical trial of ...
Only a small fraction of older adults in the early stages of Alzheimer's disease (AD) meet eligibility criteria to receive treatment with newly approved anti-amyloid drugs, largely due to the presence ...
Last July, the U.S. Food and Drug Administration (FDA) issued a notable approval for LEQEMBI® (lecanemab-irmb), the first medicine to slow the rate of cognitive decline in certain patients with early ...
Please provide your email address to receive an email when new articles are posted on . Early Alzheimer’s care should include new FDA-approved therapies like lecanemab. The guidance suggests greater ...
Findings showed blarcamesine patients had a 36.3% reduction in clinical decline based on ADAS-Cog13 scores compared with placebo at 48 weeks. Blarcamesine significantly slowed cognitive decline in ...
Early initiation of daily specialized emollient use until 2 months was associated with a reduced incidence of atopic dermatitis development among high-risk infants. Early initiation of daily ...
Recent proteomic studies have offered glimpses into the biology of early Alzheimer’s disease. Two new preprints take this approach further, describing high-throughput surveys that turned up numerous ...
Impact of an Accelerated Diagnostic Assessment Program on the Timeliness of Cancer Diagnosis and Treatment Data from 31,558 patients eligible for the AD question were analyzed. Patients treated at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results